[{"address1": "10955 Vista Sorrento Parkway", "address2": "Suite 200", "city": "San Diego", "state": "CA", "zip": "92130", "country": "United States", "phone": "858 751 4493", "website": "https://www.januxrx.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Janux Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platforms technology to treat patients with cancer. Its clinical candidates include JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor that is in Phase 1 clinical trial for the treatment of various solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, renal cell carcinoma, small cell lung cancer, pancreatic ductal adenocarcinoma, and triple-negative breast cancer. Janux Therapeutics, Inc. has strategic research collaboration agreement with Merck Sharp & Dohme Corp. to develop TRACTr product candidates. The company was incorporated in 2017 and is headquartered in San Diego, California.", "fullTimeEmployees": 109, "companyOfficers": [{"maxAge": 1, "name": "Dr. David Alan Campbell Ph.D.", "age": 64, "title": "President, CEO & Director", "yearBorn": 1960, "fiscalYear": 2024, "totalPay": 1130500, "exercisedValue": 0, "unexercisedValue": 107640504}, {"maxAge": 1, "name": "Dr. Thomas  Diraimondo Ph.D.", "age": 38, "title": "Chief Scientific Officer", "yearBorn": 1986, "fiscalYear": 2024, "totalPay": 630000, "exercisedValue": 0, "unexercisedValue": 28001912}, {"maxAge": 1, "name": "Mr. Matt  Whitmire", "title": "Vice President of Finance", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Maria  Dobek", "age": 35, "title": "Principal Accounting Officer & VP of Accounting", "yearBorn": 1989, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Charles M. Winter", "age": 55, "title": "Chief Technical Officer", "yearBorn": 1969, "fiscalYear": 2024, "totalPay": 590400, "exercisedValue": 0, "unexercisedValue": 460878}, {"maxAge": 1, "name": "Mr. James  Pennington", "title": "General Counsel & Corporate Secretary", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Janeen  Doyle", "title": "Chief Corporate & Business Development Officer", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Andy Hollman Meyer", "age": 40, "title": "Chief Business Officer", "yearBorn": 1984, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Zachariah  McIver D.O., Ph.D.", "age": 54, "title": "Chief Medical Officer", "yearBorn": 1970, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 7, "boardRisk": 7, "compensationRisk": 9, "shareHolderRightsRisk": 8, "overallRisk": 8, "governanceEpochDate": 1764547200, "compensationAsOfEpochDate": 1735603200, "executiveTeam": [], "maxAge": 86400, "priceHint": 2, "previousClose": 16.4, "open": 16.4, "dayLow": 16.0, "dayHigh": 16.54, "regularMarketPreviousClose": 16.4, "regularMarketOpen": 16.4, "regularMarketDayLow": 16.0, "regularMarketDayHigh": 16.54, "payoutRatio": 0.0, "beta": 2.814, "forwardPE": -10.31875, "volume": 2119691, "regularMarketVolume": 2119691, "averageVolume": 1387347, "averageVolume10days": 3518110, "averageDailyVolume10Day": 3518110, "bid": 12.27, "ask": 21.0, "bidSize": 2, "askSize": 2, "marketCap": 993040320, "fiftyTwoWeekLow": 15.51, "fiftyTwoWeekHigh": 66.34, "allTimeHigh": 71.71, "allTimeLow": 5.65, "priceToSalesTrailing12Months": 99.30403, "fiftyDayAverage": 26.6626, "twoHundredDayAverage": 26.547625, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "tradeable": false, "enterpriseValue": 26707294, "profitMargins": 0.0, "floatShares": 45018228, "sharesOutstanding": 60147807, "sharesShort": 7131951, "sharesShortPriorMonth": 8562496, "sharesShortPreviousMonthDate": 1760486400, "dateShortInterest": 1763078400, "sharesPercentSharesOut": 0.118599996, "heldPercentInsiders": 0.06584, "heldPercentInstitutions": 1.10141, "shortRatio": 6.19, "shortPercentOfFloat": 0.1703, "impliedSharesOutstanding": 60147807, "bookValue": 16.242, "priceToBook": 1.0165004, "lastFiscalYearEnd": 1735603200, "nextFiscalYearEnd": 1767139200, "mostRecentQuarter": 1759190400, "netIncomeToCommon": -101895000, "trailingEps": -1.67, "forwardEps": -1.6, "enterpriseToRevenue": 2.671, "enterpriseToEbitda": -0.188, "52WeekChange": -0.73398215, "SandP52WeekChange": 0.13287461, "quoteType": "EQUITY", "currentPrice": 16.51, "targetHighPrice": 150.0, "targetLowPrice": 25.0, "targetMeanPrice": 66.23529, "targetMedianPrice": 57.0, "recommendationMean": 1.26316, "recommendationKey": "strong_buy", "numberOfAnalystOpinions": 17, "totalCash": 988993024, "totalCashPerShare": 16.443, "ebitda": -142215008, "totalDebt": 22660000, "quickRatio": 35.763, "currentRatio": 35.862, "totalRevenue": 10000000, "debtToEquity": 2.32, "revenuePerShare": 0.165, "returnOnAssets": -0.10487001, "returnOnEquity": -0.12482, "grossProfits": -105154000, "freeCashflow": -42865000, "operatingCashflow": -70418000, "revenueGrowth": 21.779, "grossMargins": 0.0, "ebitdaMargins": 0.0, "operatingMargins": -3.5251, "financialCurrency": "USD", "symbol": "JANX", "language": "en-US", "region": "US", "typeDisp": "Equity", "quoteSourceName": "Nasdaq Real Time Price", "triggerable": true, "customPriceAlertConfidence": "HIGH", "hasPrePostMarketData": true, "firstTradeDateMilliseconds": 1623418200000, "postMarketChangePercent": -0.4239836, "postMarketPrice": 16.44, "postMarketChange": -0.069999695, "regularMarketChange": 0.110001, "regularMarketDayRange": "16.0 - 16.54", "fullExchangeName": "NasdaqGM", "averageDailyVolume3Month": 1387347, "fiftyTwoWeekLowChange": 1.0, "fiftyTwoWeekLowChangePercent": 0.06447453, "fiftyTwoWeekRange": "15.51 - 66.34", "fiftyTwoWeekHighChange": -49.829994, "fiftyTwoWeekHighChangePercent": -0.7511305, "fiftyTwoWeekChangePercent": -73.39822, "earningsTimestampStart": 1762462800, "regularMarketChangePercent": 0.670735, "regularMarketPrice": 16.51, "corporateActions": [], "postMarketTime": 1764982007, "regularMarketTime": 1764968400, "exchange": "NGM", "messageBoardId": "finmb_676965261", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EST", "gmtOffSetMilliseconds": -18000000, "market": "us_market", "esgPopulated": false, "marketState": "CLOSED", "shortName": "Janux Therapeutics, Inc.", "longName": "Janux Therapeutics, Inc.", "earningsTimestampEnd": 1762462800, "isEarningsDateEstimate": true, "epsTrailingTwelveMonths": -1.67, "epsForward": -1.6, "epsCurrentYear": -1.97572, "priceEpsCurrentYear": -8.356447, "fiftyDayAverageChange": -10.152599, "fiftyDayAverageChangePercent": -0.38078055, "twoHundredDayAverageChange": -10.037624, "twoHundredDayAverageChangePercent": -0.3780988, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "ipoExpectedDate": "2021-06-11", "averageAnalystRating": "1.3 - Strong Buy", "cryptoTradeable": false, "displayName": "Janux Therapeutics", "trailingPegRatio": null, "__fetch_time": "2025-12-06"}]